ClinicalTrials.gg
RecruitingNCT07439120Updated Nov 19, 2026

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

An Early Phase 1 interventional study of ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 in Urothelial Carcinoma (UC), sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Carcinoma, Transitional Cell with a site in China — 53 open to participants now, 58 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.

Planned enrollment
68th of 71
10 · median 58
Started
2026
with 19 others
Phase 1
11 of 90
7 open now
Primary completion
2026-12
later than 19 of 57 live
Registered
71st of 90
by date

Among the 90 studies in Carcinoma, Transitional Cell with a site in China, this one is the 68th largest by planned enrollment of the 71 interventional ones that give a count, is one of 20 that started in 2026, is one of 11 in phase 1, reaches primary completion later than 19 of the 57 other live ones, and was the 71st registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

53 of the 90 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Carcinoma, Transitional Cell with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, single-arm, interventional clinical trial designed to investigate the safety of ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 in patients with advanced metastatic solid tumors; to evaluate the pharmacokinetics, biodistribution, and radiation dosimetry of ¹⁷⁷Lu-BRP-020063 in patients with metastatic solid tumors; and to preliminarily explore its therapeutic efficacy. The study plans to enroll 10 patients to receive ⁶⁸Ga-BRP-020063 PET/CT imaging, among whom 5 patients positive for ⁶⁸Ga-BRP-020063 will be selected to receive a low dose of ¹⁷⁷Lu-BRP-020063. The results of this study will provide a basis for the design of subsequent studies involving higher doses of ¹⁷⁷Lu-BRP-020063.

03

Conditions studied

  • Urothelial Carcinoma (UC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, regardless of gender;
  2. Patients with a confirmed diagnosis of advanced solid tumor (preferably urothelial carcinoma, followed by breast cancer);
  3. Willing to provide archived or freshly biopsied tumor tissue specimens (recommended within the past 2 years);
  4. Performance status () score of 0-1;
  5. Adequate organ function:

    • Complete Blood Count: White blood cell count ≥ 3.0 × 10⁹/L, ≥ 1.5 × 10⁹/L, ≥ 90 g/L, count ≥ 75 × 10⁹/L;
    • Liver function: Total ≤ 2.5 × , ≤ 3 × ULN, aspartate aminotransferase ≤ 3 × ULN;
    • Renal function: ≥ 50 mL/min (Cockcroft-Gault formula);
    • Coagulation function: ≤ 1.5 × ULN, activated partial thromboplastin time ≤ 1.5 × ULN, international normalized ratio ≤ 1.5 × ULN;
  6. Subjects of must voluntarily adopt effective during the treatment period and for 6 months after the last dose of the drug (for females);
  7. Willing to participate in this trial and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with Nectin-4-targeted drugs (including clinical trials);
  2. Inability to complete PET/CT or SPECT/CT examinations (including inability to lie flat, claustrophobia, radiophobia, etc.);
  3. Participation in drug or device clinical studies within 4 weeks prior to the first dose;
  4. Presence of severe or uncontrolled underlying diseases, including but not limited to:

    1. Class II or higher congestive heart failure, or severe arrhythmia requiring medication;
    2. Severe cardiovascular/cerebrovascular or valvular diseases;
    3. Poorly controlled diabetes or hypertension;
  5. Inability to tolerate intravenous administration or difficulty with venipuncture (e.g., history of needle or blood phobia);
  6. Active infection within 4 weeks prior to the first dose;
  7. Women who are planning pregnancy, currently pregnant, or breastfeeding;
  8. Allergy to radioactive rays or other severe allergic history;
  9. History of neurological with associated symptoms;
  10. Concurrent other ;
  11. Undergone general anesthesia surgery within 4 weeks prior to the first dose;
  12. Other conditions deemed by the investigator as unsuitable for inclusion in the clinical study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 Treatment Arm

    Drug: ⁶⁸Ga/¹⁷⁷Lu-BRP-020063

Interventions

  • Drug⁶⁸Ga/¹⁷⁷Lu-BRP-020063

    68Ga-BRP-020063 Injection (Diagnostic Phase): All subjects will receive a single administration of 68Ga-BRP-020063 injection. The dose of 5 mCi (185 MBq), within an acceptable range of 3-7 mCi (111-259 MBq), will be delivered via rapid consecutive intravenous bolus injection in a volume not exceeding 10 mL, followed by a saline flush. 177Lu-BRP-020063 Injection (Therapeutic Phase): Five subjects who show positive results on the 68Ga-BRP-020063 PET/CT scan will be selected to receive a single administration of 177Lu-BRP-020063 injection. A dose of 40 mCi (1.48 GBq), within an acceptable range of 30-50 mCi (1.11-1.85 GBq), will be administered via intravenous infusion over approximately 20 minutes using an infusion pump, followed by a saline flush.

06

What researchers measure

Primary outcomes

  1. Adeverse Events

    Time frame: From enrolment to 4 weeks after the first dose

Secondary outcomes

  1. PK Parameters

    AUC(0-∞)

    Time frame: From administration up to 168 hours post-dose

  2. Biodistribution

    Perform whole-body SPECT/CT to determine radioactivity (%ID) in major organs over time for biodistribution assessment.

    Time frame: From administration up to 168 hours post-dose

  3. Radiation Dosimetry

    Time frame: from administration up to 168 hours post-dose

Other outcomes

  1. ORR

    Time frame: be assessed at 6-week or 8-week intervals from the start of treatment until disease progression to up to 1 year.

  2. DCR

    Time frame: be assessed at 6-week or 8-week intervals from the start of treatment until disease progression to up to 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 37 non-industry phase 1 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 73. This study's planned 8 months is below that.

Counting every sponsor, half of 99 studies reached it within 45 months; a quarter within 31 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2026 → Dec 2026 and completion Aug 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 27, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Dec 31, 2026was Aug 2026
CompletionEst.
Dec 31, 2026was Aug 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Dec 31, 2026
Nov 19, 2026
Study completion
Aug 31, 2026→Dec 31, 2026
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Aug 31, 2026→Dec 31, 2026
    Study completion Aug 31, 2026→Dec 31, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07439120
Responsible party
Yan Xing (Medical Director, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Feb 27, 2026
Start date
Apr 13, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

Yan Xing, Dr.
Contact
xy.1@163.com
+862163246311

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion